Dörner et al. Remibrutinib (BTKi) in pSS. + study in pSS! Improved ESSDAI (disease activity), no effect ESSPRI (PRO), trend to improve salivary flow, + effect on multiple labs. @RheumNow #ACR22 Abstr#1113 https://t.co/m2rvXbqq7b https://t.co/jQLyP66zX9
Links:
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a…
https://acrabstracts.org/abstract/remibrutinib-lou064-in-sjogrens-syndrome-safe…
13-11-2022